EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis

Shusuke Kumazaki, Hayato Hikita, Yuki Tahata, Ji Hyun Sung, Kenji Fukumoto, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yoichi Sasaki, Kumiko Shirai, Yoshinobu Saito, Takahiro Kodama and 11 more

Alimentary Pharmacology & Therapeutics · 2024-08 · 60 (3) · 327-339

DOI: 10.1111/apt.18063 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-06-03. Written by Shusuke Kumazaki and 22 co-authors. Institution: Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan. Major MEDLINE topics: Growth Differentiation Factor 15, Liver Neoplasms, Liver Cirrhosis, Biomarkers. Cited 27 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Aims Although metabolic dysfunction‐associated steatotic liver disease (MASLD) patients with a Fib‐4 index >1.3 are recommended for fibrosis evaluation via elastography or biopsy, a more convenient method identifying high‐risk populations requiring follow‐up is needed. We explored the utility of serum levels of growth differentiation factor‐15 (GDF15), a cell stress‐responsive cytokine related to metabolic syndrome, for stratifying the risk of clinical events in MASLD patients.

Methods

Serum GDF15 levels were measured in 518 biopsy‐performed MASLD patients, 216 MASLD patients for validation, and 361 health checkup recipients with MASLD.

Results

In the biopsy‐MASLD cohort, multivariate analysis indicated that the serum GDF15 level was a risk factor for liver cancer, independent of the fibrosis stage or Fib‐4 index. Using a GDF15 cutoff of 1.75 ng/mL based on the Youden index, high‐GDF15 patients, regardless of fibrosis status, had a higher liver cancer incidence rate. While patients with a Fib‐4 index 1.3 developed liver cancer and decompensated liver events at significantly higher rates and had poorer prognoses. In the validation cohort, high‐GDF15 patients had significantly higher incidences of liver cancer and decompensated liver events and poorer prognoses than low‐GDF15 patients, whether limited to high‐Fib‐4 patients. Among health checkup recipients with MASLD, 23.0% had a Fib‐4 index >1.3, 2.7% had a Fib‐4 index >1.3 and >1.75 ng/mL GDF15.

Conclusions

Serum GDF15 is a biomarker for liver cancer with high predictive capability and is useful for identifying MASLD patients requiring regular surveillance.

Subjects

MeSH terms (MEDLINE)

Growth Differentiation Factor 15Liver NeoplasmsLiver CirrhosisBiomarkersHumansMaleFemaleMiddle AgedAgedPredictive Value of TestsRisk FactorsFatty LiverAdultBiopsyMetabolic Syndrome

Substances

Growth Differentiation Factor 15GDF15 protein, humanBiomarkers

Authors and institutions

  • Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Kaizuka City Hospital, Osaka, Japan.
  • Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

ORCID profiles: Hidenori Toyoda, Goki Suda, Tetsuo Takehara

Funding

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Cite

APA

Kumazaki, S., Hikita, H., Tahata, Y., Sung, J. H., Fukumoto, K., Myojin, Y., Sakane, S., Murai, K., Sasaki, Y., Shirai, K., Saito, Y., Kodama, T., Kakita, N., Takahashi, H., Toyoda, H., Suda, G., Morii, E., Kojima, T., Ebihara, T., …, & Takehara, T. (2024). Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Alimentary Pharmacology & Therapeutics, 60(3), 327-339. https://doi.org/10.1111/apt.18063

Vancouver

Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Alimentary Pharmacology & Therapeutics. 2024;60(3):327-339. doi:10.1111/apt.18063

BibTeX
@article{Kumazaki2024,
  author = {Kumazaki, Shusuke and Hikita, Hayato and Tahata, Yuki and Sung, Ji Hyun and Fukumoto, Kenji and Myojin, Yuta and Sakane, Sadatsugu and Murai, Kazuhiro and Sasaki, Yoichi and Shirai, Kumiko and Saito, Yoshinobu and Kodama, Takahiro and Kakita, Naruyasu and Takahashi, Hirokazu and Toyoda, Hidenori and Suda, Goki and Morii, Eiichi and Kojima, Takashi and Ebihara, Takeshi and Shimizu, Kentaro and Sasaki, Yutaka and Tatsumi, Tomohide and Takehara, Tetsuo},
  title = {Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {3},
  pages = {327--339},
  doi = {10.1111/apt.18063}
}
Start for free →